Oct 26, 2021 04:43 PM (GMT+8) · EqualOcean
Hengrui pharmaceutical announced that Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, has received the approval notice of drug clinical trial on hrs9531 injection approved and issued by the State Food and Drug Administration and will carry out clinical trial in the near future. HRS9531 injection is an innovative medicine developed independently by the company. Its indication is type 2 diabetes. There are no drugs with the same target on the market at home and abroad.